Tc-99m-HMDP bone uptake quantification and plasma osteocalcin levels in hemodialysis patients--a preliminary study.

Abstract

In this preliminary study plasma osteocalcin levels and Tc-99m-HMDP (Technetium 99m hydroxymetylene diphosphonate) bone uptake (BU) were measured in 10 chronic end-stage renal failure patients who were on maintenance hemodialysis. The aim of this study was to determine the correlation between bone uptake and osteocalcin-a sensitive and specific marker of osteoblastic activity. There was a statistically significant increase in both 20 and 180 minute uptake in the patient group (36 +/- 2.7 and 39 +/- 3.6) when compared to the normal volunteers (32 +/- 3.1 and 19 +/- 2.7). Plasma osteocalcin levels were also significantly high (24.5 +/- 5.6 ng/ml) when compared with normal values (6.5 +/- 2.3 ng/ml). The correlations between osteocalcin and 20 and 180 min BU were high (r = 0.62 and 0.72 respectively). In conclusion, our preliminary study suggests that, in hemodialysis patients, Tc-99m-HMDP bone uptake quantification is a sensitive and non-invasive method for showing increased osteoblastic activity.

• Authors: U Karayalcin, B Karayalcin, G Yakupoglu, A Yildiz, M Erkilic
• Journal: Annals of nuclear medicine (Ann Nucl Med) Vol. 6 Issue 1 Pg. 9-12 (Feb 1992) ISSN: 0914-7187 [Print] Japan
• PMID: 1520575 (Publication Type: Journal Article)

Chemical References

• Osteocalcin
• technetium Tc 99m hydroxymethylene diphosphonate
• Technetium Tc 99m Medronate

Topics

• Adolescent
• Adult
• Bone and Bones (diagnostic imaging, metabolism)
• Child
• Female
• Humans
• Male
• Middle Aged
• Osteoblasts (physiology)
• Osteocalcin (blood)
• Radionuclide Imaging
• Renal Dialysis
• Technetium Tc 99m Medronate (pharmacokinetics)